Dose-escalation, Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Patients With r/r NHL and r/r B-cell ALL
NCT ID: NCT03666000
Last Updated: 2025-03-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1
129 participants
INTERVENTIONAL
2019-03-11
2027-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia
NCT01371630
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
NCT06564038
Phase I, Open-label, Dose Escalation of AZD4877 in Hematologic Malignancies
NCT00460460
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
NCT01861002
Phase I/II, Open-label, Multi-center, Two Part Dose-escalation, Safety, Pharmacokinetics (PK) and Efficacy Study of AZD4877 in Patients With Acute Myelogenous Leukemia (AML)
NCT00486265
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Dose Level 1
Azer-cel 3 x 10\^5 CAR T cells per kilogram (kg) body weight.
Route of Administration: Intravenous infusion.
Azer-cel
Infusion of Allogeneic Anti-CD19 CAR T cells
Fludarabine
Specified dose on specified days
Cyclophosphamide
Specified dose on specified days
Dose Level 2
Azer-cel, 1 x 10\^6 CAR T cells per kg body weight
Azer-cel
Infusion of Allogeneic Anti-CD19 CAR T cells
Fludarabine
Specified dose on specified days
Cyclophosphamide
Specified dose on specified days
Dose Level 3a
Azer-cel, 3 x 10\^6 CAR T cells per kg body weight.
Azer-cel
Infusion of Allogeneic Anti-CD19 CAR T cells
Fludarabine
Specified dose on specified days
Cyclophosphamide
Specified dose on specified days
Dose Level 4
Azer-cel, 6 x 10\^6 CAR T cells per kg body weight as 2 administrations of 3 x 10\^6 CAR T cells per kg body weight administered after a single lymphodepletion.
Azer-cel
Infusion of Allogeneic Anti-CD19 CAR T cells
Fludarabine
Specified dose on specified days
Cyclophosphamide
Specified dose on specified days
Dose Level 4b
Azer-cel, 500 x 10\^6 CAR T cells (flat dose)
Azer-cel
Infusion of Allogeneic Anti-CD19 CAR T cells
Fludarabine
Specified dose on specified days
Cyclophosphamide
Specified dose on specified days
IL-2
Specified dose on specified days
Bendamustine
Specified dose on specified days
Dose level 4c
Azer-cel, 1000 x 10\^6 CAR T cells (flat dose) given as 2 administrations of 500 × 106 cells/per dose on Day 0 and Day 5.
Azer-cel
Infusion of Allogeneic Anti-CD19 CAR T cells
Fludarabine
Specified dose on specified days
Cyclophosphamide
Specified dose on specified days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Azer-cel
Infusion of Allogeneic Anti-CD19 CAR T cells
Fludarabine
Specified dose on specified days
Cyclophosphamide
Specified dose on specified days
IL-2
Specified dose on specified days
Bendamustine
Specified dose on specified days
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participant has unequivocal r/r CD19+ B-ALL that has been confirmed by morphology, flow cytometry, or a validated minimal residual disease (MRD) assay.
* Participants with Philadelphia chromosome positive disease can be eligible if they are intolerant to tyrosine kinase inhibitor therapy or if they have r/r disease.
Criteria for NHL:
* Participant has unequivocal aggressive CD19+ r/r B-cell NHL that is confirmed by archived tumor biopsy tissue from last relapse after CD19-directed therapy and corresponding pathology report. Alternatively, if at least 1 tumor involved site is accessible at time of Screening, the participant's diagnosis is confirmed by pretreatment biopsy (excisional when possible) or by flow cytometry of fine needle aspirate (FNA). If a participant never had a CR, a sample from the most recent biopsy is acceptable. NHL subtypes included but are not limited to:
* For Phase 1 Dose Escalation:
* Diffuse large B-cell lymphoma (DLBCL) including Richter's transformation
* FL including Grade 3 or transformed FL
* High-grade B-cell lymphoma
* Primary mediastinal lymphoma
* For Phase 1b Dose Expansion:
* DLBCL not otherwise specified (NOS)
* High grade B-Cell Lymphoma
* DLBCL transformed from the following indolent lymphoma subtypes (Follicular lymphoma, Marginal Zone lymphoma and Waldenstrom's Macroglobulinemia)
* Participant has measurable or detectable (for example positron emission tomography-positive) disease according to the Lugano Classification.
* Participant must have received at least 2 lines of prior anti-cancer therapy for the disease under study, including at least 1 chemoimmunotherapy regimen (e.g., anti-CD20 monoclonal antibody plus chemotherapy), consistent with standard of care treatment guidance (e.g., National Comprehensive Cancer Network \[NCCN\]), unless no second line therapy of known benefit exists for a given subject. For Richter's transformation, only 1 prior line of therapy is required for the DLBCL component.
* Participant has received no more than 7 systemic lines of anti-cancer therapy for the disease under study.
* Participants previously treated with CD19-directed autologous CAR T therapies have received no more than 2 lines of therapy after administration of their previous CAR T product.
* Expansion cohort only: Participants must have received autologous CD19-directed CAR T therapy and demonstrated clinical response to the treatment at Day 28 or later, followed by relapse or progression.
Criteria for both B-ALL and NHL:
* Eastern Cooperative Oncology Group performance status score of 0 or 1.
* An estimated life expectancy of at least 12 weeks according to the investigator's judgment.
* Seronegative for human immunodeficiency virus antibody (i.e., intact immune function).
* Participant has adequate bone marrow, renal, hepatic, pulmonary, and cardiac function defined as:
1. Estimated glomerular filtration rate (eGFR) \>30 mL/min/1.73 m2 (calculated using the CKD-EPI equation \[Levey et al, 2009\]). For participants receiving an LD regimen that contains 4 days of Fludarabine, an eGFR \>=60 mL/min/1.73 m2 (calculated using the CKD-EPI equation) is required. If there is a concern that eGFR calculation is not an accurate reflection of renal function, a 24-hour urine collection for creatinine clearance may be used at the investigator's discretion.
2. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels both ≤3 times of upper limit of normal (ULN), unless there is suspected disease in the liver.
3. Total bilirubin \<2.0 mg/dL, except in participants with Gilbert's syndrome.
4. Platelet count ≥50,000/μL and absolute neutrophil count of ≥1000/ μL. Platelet transfusions within 14 days of screening are not allowed except for participants in B-ALL disease cohort with extensive bone marrow disease burden, in which case adequate bone marrow recovery after prior treatment is required to be documented. NHL participants with a platelet count \<50,000/μL and absolute neutrophil count (ANC) of \<1000/ μL may be enrolled with Medical Monitor approval if there is documentation of significant bone marrow involvement by disease and in the Investigator's assessment, no other reasonable etiology for the low counts.
5. Left ventricular ejection fraction \>45% as assessed by echocardiogram (ECHO) or multiple gated acquisition scan performed within 1 month before starting lymphodepleting chemotherapy. ECHO results performed within 6 months before Screening and at least 28 days after the last cancer treatment may be acceptable if the participant has not received any treatment with cardiotoxicity risks.
6. No clinically significant evidence of pericardial effusion or pleural effusion causing clinical symptoms and needing immediate intervention, based on the investigator's opinion. Any known effusion must be stable without need for drainage within 2 weeks of enrollment.
7. No clinically significant renal/pulmonary comorbidities.
8. Baseline oxygen saturation \>92% on room air.
Exclusion Criteria
* Burkitt cell (L3 ALL) or mixed-lineage acute leukemia.
Criteria for NHL:
* Requirement for urgent therapy due to tumor mass effects such as bowel obstruction or blood vessel compression.
* Active hemolytic anemia.
Criteria for B-ALL and NHL:
* No active central nervous system (CNS) disease. Subjects with a prior history of CNS involvement that has been adequately treated ≥3 months prior to study consent and without symptoms or clinical suspicion of relapsed CNS disease may be enrolled.
* History of another primary malignancy that has not been in remission for at least 2 years with the following exceptions:
* Curatively treated basal or squamous cell carcinoma or melanoma of the skin or in situ carcinoma of the breast or cervix
* Low-grade, early-stage prostate cancer (Gleason score 6 or below, Stage 1 or 2) with no requirement for therapy at any time
* Completely resected Stage 1 solid tumor with low risk for recurrence within 2 years
* In the case of Richter's transformation, participants may be enrolled with ongoing chronic lymphocytic leukemia/small lymphocytic lymphoma.
* Any form of primary immunodeficiency (e.g., severe combined immunodeficiency disease).
* History of hepatitis B or hepatitis C currently receiving ongoing antiviral therapy.
* Any known uncontrolled cardiovascular disease at the time of Screening that, in the investigator's opinion, renders the participant ineligible, including but not limited to:
1. Active ventricular or atrial dysrhythmia ≥ Grade 2, bradycardia ≥ Grade 2.
2. Myocardial infarction within 6 months before Screening.
3. Pulmonary embolism, deep vein thrombosis, or any other significant coagulopathy including disseminated intravascular coagulation.
* History of hypertension crisis or hypertensive encephalopathy within 3 months prior to Screening. In case of hypertensive crisis caused by omission of well-established treatment regimen, transient and promptly stabilized, enrollment must be discussed and agreed upon with sponsor and medical monitor.
* History of severe immediate hypersensitivity reaction to any of the agents used in this study.
* Presence of a CNS disorder that, in the opinion of the investigator, renders the participant ineligible for treatment.
* Abnormal findings during the Screening Period or any other medical condition(s) or laboratory findings that, in the opinion of the investigator, might jeopardize the participant's safety.
* History of concomitant genetic syndrome such as Fanconi anemia, Kostmann syndrome, Shwachman-Diamond syndrome, or any other known bone marrow failure syndrome.
* Active uncontrolled autoimmune disease requiring active immunosuppression at the time of Screening (excluding participants needing steroids for physiologic replacement).
* Participant has received stem cell transplant within 90 days before Screening.
* Participant has active GvHD symptoms.
* Participant has received a systemic biologic agent for treatment of the disease under study within 28 days of LD, other systemic anti-cancer therapy within 10 days or 5 half-lives (whichever is shorter) of LD, and no pulse steroid for disease control within 3 days of LD. Note: This criterion does not apply if the subject has clear evidence of disease progression after such an agent has been administered and all AEs have resolved to a Grade 2 or less in severity. This should be discussed with the Medical Monitor for confirmation
* Radiotherapy within 4 weeks before Screening should be discussed with monitor and determined on a case-by-case basis.
* Presence of pleural/peritoneal/pericardial catheter, as well as permeant biliary and ureteral stents (does not apply to intravenous lines).
* Participant has received live vaccine within 4 weeks before Screening. Non-live virus vaccines are not excluded.
* Participant has received CD19-directed therapy other than autologous CD19-directed CAR T therapy within 90 days of the anticipated start date of LD.
Additional criteria apply
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Imugene Limited
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
John Byon, MD, PhD
Role: STUDY_CHAIR
Imugene Limited
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Banner MD Anderson Cancer Center
Gilbert, Arizona, United States
City of Hope
Duarte, California, United States
H. Lee Moffitt Cancer Center
Tampa, Florida, United States
Winship Cancer Institute Emory University
Atlanta, Georgia, United States
Northside Hospital Cancer Institute
Atlanta, Georgia, United States
University of Maryland
Baltimore, Maryland, United States
Tufts Medical Center
Boston, Massachusetts, United States
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Barbara Ann Karmanos Cancer Institute (Wayne State University)
Detroit, Michigan, United States
University of Minnesota
Minneapolis, Minnesota, United States
Weill Cornell Medical College - NY Presbyterian Hospital
New York, New York, United States
Columbia University Irving Medical Center/New York Presbyterian Hospital
New York, New York, United States
Duke University
Durham, North Carolina, United States
Ohio State University
Columbus, Ohio, United States
Lifespan Cancer Institute at Rhode Island Hospital
Providence, Rhode Island, United States
Baylor University Medical Center
Dallas, Texas, United States
MD Anderson
Houston, Texas, United States
Medical College of Wisconsin
Milwaukee, Wisconsin, United States
Royal Prince Alfred Hospital
Camperdown, New South Wales, Australia
Liverpool Hospital
Liverpool, New South Wales, Australia
Royal Adelaide Hospital
Adelaide, South Australia, Australia
St Vincent's Hospital Melbourne
Fitzroy, Victoria, Australia
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Clinical Trials
Role: primary
Clinical Research
Role: primary
Clinical Research
Role: primary
Clinical Trials
Role: primary
Clinical Trials
Role: primary
Clinical Trials
Role: primary
Clinical Trials
Role: primary
Clinical Trials
Role: primary
Clinical Research
Role: primary
Clinical Trials
Role: primary
Clinical Trials
Role: primary
Clinical Trials
Role: primary
Clinical Trials
Role: primary
Clinical Trials
Role: primary
Dr Vinay Vanguru
Role: primary
Dr Nagendra P Sungala
Role: primary
Dr Danielle Blunt
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PBCAR0191-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.